FDA approves Moderna's first mRNA flu shot, mFlusiva

The US Food and Drug Administration has approved mFlusiva, Moderna's first mRNA-based influenza vaccine. The shot received traditional approval for adults aged 50 to 64 and accelerated approval for those 65 and older.